Is this the conclusive evidence for ticagrelor monotherapy in acute coronary syndromes?

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan 20090, Italy; Cardio Center, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy. Electronic address: giulio.stefanini@hunimed.eu.
² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan 20090, Italy; Cardio Center, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy.

Comment

Giulio G Stefanini et al. Lancet. 2024.

. 2024 Sep 7;404(10456):908-909.

doi: 10.1016/S0140-6736(24)01678-7. Epub 2024 Aug 31.

¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan 20090, Italy; Cardio Center, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy. Electronic address: giulio.stefanini@hunimed.eu.
² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan 20090, Italy; Cardio Center, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy.

No abstract available

Conflict of interest statement

We declare no competing interests.

De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.
Valgimigli M, Hong SJ, Gragnano F, Chalkou K, Franzone A, da Costa BR, Baber U, Kim BK, Jang Y, Chen SL, Stone GW, Hahn JY, Windecker S, Gibson MC, Song YB, Ge Z, Vranckx P, Mehta S, Gwon HC, Lopes RD, Dangas GD, McFadden EP, Angiolillo DJ, Leonardi S, Heg D, Calabrò P, Jüni P, Mehran R, Hong MK; Single Versus Dual Antiplatelet Therapy (Sidney-4) collaborator group. Valgimigli M, et al. Lancet. 2024 Sep 7;404(10456):937-948. doi: 10.1016/S0140-6736(24)01616-7. Epub 2024 Aug 31. Lancet. 2024. PMID: 39226909